Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the National Health Service (NHS) in England. 10 July 2024
Biosimilars
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Pyzchiva (ustekinumab-ttwe) submitted by South Korean firm Samsung Bioepis. 1 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Sofdra (sofpironium) topical gel, 12.45%. 20 June 2024
Biotechnology
US immuno-dermatology specialist biotech Dermavant Sciences, a subsidiary of Roivant Sciences, has achieved positive Phase III trial results with Vtama (tapinarof), a nonsteroidal, topical AhR-modulating agent, in atopic dermatitis (AD). 14 June 2024
Biotechnology
Belgium’s UCB is sharing results from three studies supporting the value of Cimzia (certolizumab pegol) for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels. 13 June 2024
Biotechnology
US clinical-stage biotech Connect Biopharma has made a number of appointments to strengthen its leadership team. 13 June 2024
Biotechnology
US biotech Triveni Bio today announced that Dr Bhaskar Srivastava has joined the company as chief medical officer (CMO). 12 June 2024
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy. 10 June 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved the recent supplemental New Drug Application (sNDA), submitted by Spanish dermatology focused drugmaker Almirall, to expand the use area for its drug Klisyri (tirbanibulin) to up to 100 cm. 10 June 2024
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze